TRLV
The green rush got a blue-chip makeover
Trulieve Cannabis just did something no other U.S. marijuana company has pulled off: it listed on the NYSE under TRLV. That’s a big deal in a sector that’s spent years hanging out in the market’s awkward teen phase — mostly over-the-counter, lightly loved, and always waiting for the next policy plot twist.
Why investors care
The stock didn’t exactly moon on debut — it actually closed lower on Wednesday — but the symbolism here is bigger than the tape. A major exchange listing can mean more visibility, more credibility, and potentially a wider pool of institutional investors who’d rather not touch OTC names with a ten-foot pole.
Trulieve says the Trump administration’s move to reclassify cannabis to Schedule III helped clear the path for NYSE approval. The company also split out its medical cannabis business from adult-use operations, which sounds very corporate-reorg-y but apparently did the trick.
The sector is waking up
The ripple effects are already showing up:
- MSOS, the big U.S. cannabis ETF, hit a 2026 high this week, and Trulieve makes up about 30% of its assets.
- Curaleaf recently announced a reverse stock split as it eyes its own uplisting path.
- Other names like Verano are also being watched for a potential move to a major exchange.
Big picture: Trulieve’s NYSE debut isn’t just a vanity metric. If exchange access and federal policy keep loosening, the whole cannabis capital markets playbook could get rewritten — and fast.